On July 29, 2011, the Federal Circuit upheld the validity of the patents covering Finnegan client Eli Lilly and Company’s attention deficit hyperactivity disorder treatment, Strattera®. The Federal Circuit found the patent is valid and enforceable until it expires in May 2017, finding that a U.S. Patent and Trademark Office rule that regulates patent submission had been misinterpreted by the lower court. Generic-drug makers Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., Actavis, and Apotex had hoped to invalidate the patent in order to market generic versions of Lilly’s blockbuster drug. Finnegan represented Lilly in this matter.